Your browser is no longer supported. Please, upgrade your browser.
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own0.10% Shs Outstand67.88M Perf Week-4.39%
Market Cap4.21B Forward P/E- EPS next Y-3.48 Insider Trans-3.62% Shs Float66.83M Perf Month5.37%
Income-166.70M PEG- EPS next Q-0.82 Inst Own74.80% Short Float10.13% Perf Quarter76.14%
Sales81.10M P/S51.87 EPS this Y26.00% Inst Trans-0.13% Short Ratio3.38 Perf Half Y40.44%
Book/sh9.04 P/B6.99 EPS next Y-0.30% ROA-24.60% Target Price50.75 Perf Year93.27%
Cash/sh9.17 P/C6.89 EPS next 5Y- ROE-32.00% 52W Range27.01 - 99.95 Perf YTD-9.86%
Dividend- P/FCF- EPS past 5Y0.70% ROI-34.30% 52W High-36.77% Beta1.91
Dividend %- Quick Ratio9.30 Sales past 5Y123.40% Gross Margin- 52W Low133.99% ATR4.40
Employees235 Current Ratio9.30 Sales Q/Q-96.30% Oper. Margin- RSI (14)53.26 Volatility6.19% 6.66%
OptionableYes Debt/Eq0.00 EPS Q/Q-91.10% Profit Margin- Rel Volume1.07 Prev Close61.00
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume2.00M Price63.20
Recom2.70 SMA20-1.51% SMA5015.01% SMA20025.14% Volume2,149,475 Change3.61%
Sep-10-21Upgrade Oppenheimer Perform → Outperform $42 → $80
Aug-09-21Upgrade Truist Hold → Buy $45 → $80
Aug-05-21Upgrade Evercore ISI Underperform → Outperform $20 → $60
Jun-04-21Resumed Robert W. Baird Outperform $44
May-04-21Initiated RBC Capital Mkts Sector Perform $40
Apr-16-21Initiated Goldman Sell $20
Mar-22-21Initiated Credit Suisse Outperform $58
Mar-01-21Downgrade Barclays Overweight → Equal Weight $46
Feb-26-21Downgrade Truist Buy → Hold $45
Jan-19-21Downgrade Morgan Stanley Equal-Weight → Underweight $64 → $45
Jan-07-21Downgrade Raymond James Outperform → Mkt Perform
Dec-10-20Upgrade Wells Fargo Equal Weight → Overweight $69
Nov-03-20Initiated Robert W. Baird Underperform $14
Jun-18-20Resumed SunTrust Buy $45
Feb-21-20Initiated Wells Fargo Equal Weight $28
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Sep-13-21 08:00AM  
Sep-09-21 12:37PM  
Sep-08-21 09:00AM  
Sep-07-21 04:00PM  
Sep-03-21 11:31AM  
Sep-02-21 08:00AM  
Sep-01-21 08:15AM  
Aug-23-21 07:00AM  
Aug-20-21 04:20PM  
Aug-17-21 10:21AM  
Aug-12-21 05:52AM  
Aug-09-21 06:05PM  
Aug-05-21 12:43PM  
Aug-04-21 05:30PM  
Aug-02-21 09:29AM  
Jul-30-21 05:50PM  
Jul-29-21 09:00AM  
Jul-28-21 07:00AM  
Jul-26-21 09:00AM  
Jul-23-21 07:01AM  
Jul-22-21 02:25PM  
Jul-19-21 08:25PM  
Jul-18-21 04:00AM  
Jul-16-21 11:02AM  
Jul-15-21 08:19AM  
Jul-09-21 04:04PM  
Jul-07-21 08:34AM  
Jul-02-21 12:48PM  
Jun-29-21 09:55AM  
Jun-28-21 04:25PM  
Jun-25-21 06:01AM  
Jun-24-21 11:00AM  
Jun-23-21 07:00AM  
Jun-15-21 04:01PM  
Jun-14-21 09:00AM  
Jun-11-21 06:00AM  
Jun-07-21 07:11AM  
Jun-05-21 08:08AM  
Jun-04-21 11:31AM  
Jun-03-21 03:14AM  
May-17-21 06:15PM  
May-11-21 08:00AM  
May-05-21 04:30PM  
May-04-21 09:00AM  
May-03-21 05:59PM  
May-01-21 07:11AM  
Apr-28-21 07:01AM  
Apr-27-21 07:52AM  
Apr-19-21 03:31AM  
Apr-16-21 03:51PM  
Apr-07-21 10:58AM  
Apr-02-21 08:06AM  
Mar-29-21 05:52AM  
Mar-27-21 11:31AM  
Mar-11-21 12:06PM  
Mar-09-21 11:52AM  
Mar-06-21 10:12AM  
Mar-04-21 11:36PM  
Feb-27-21 09:23AM  
Feb-26-21 09:04AM  
Feb-25-21 01:00PM  
Feb-23-21 02:29PM  
Feb-20-21 09:03AM  
Feb-18-21 04:02PM  
Feb-17-21 06:30AM  
Feb-12-21 05:45PM  
Feb-10-21 04:42PM  
Feb-08-21 08:00AM  
Feb-05-21 06:10AM  
Feb-04-21 05:45PM  
Jan-26-21 06:30AM  
Jan-25-21 05:45PM  
Jan-24-21 07:10AM  
Jan-20-21 11:31PM  
Jan-19-21 04:01PM  
Jan-18-21 08:41AM  
Jan-15-21 06:12PM  
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTSON MICHELLEChief Financial OfficerAug 09Option Exercise30.652,50076,62531,235Aug 10 04:33 PM
ROBERTSON MICHELLEChief Financial OfficerAug 09Sale60.002,500150,00028,735Aug 10 04:33 PM
Hopfield JessicaDirectorMar 03Buy45.515,800263,97022,700Mar 05 04:13 PM
MULLEN JAMES CCEOMar 02Buy46.2725,0001,156,80035,000Mar 04 04:17 PM
Collins CynthiaCEOFeb 09Sale66.651,26284,11243,760Feb 10 04:26 PM
ROBERTSON MICHELLEChief Financial OfficerJan 12Sale78.271,568122,72718,432Jan 13 04:11 PM
Albright CharlesEVP/Chief Scientific OfficerDec 15Option Exercise16.5110,000165,10034,907Dec 17 06:58 PM
Albright CharlesEVP/Chief Scientific OfficerDec 15Sale63.2210,000632,15624,907Dec 17 06:58 PM
Albright CharlesEVP/Chief Scientific OfficerDec 09Option Exercise16.5110,000165,10034,907Dec 11 04:14 PM
Albright CharlesEVP/Chief Scientific OfficerDec 09Sale45.0010,000450,00024,907Dec 11 04:14 PM
Albright CharlesEVP/Chief Scientific OfficerDec 07Option Exercise16.5120,000330,20044,907Dec 08 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerDec 07Sale40.0220,000800,40024,907Dec 08 04:12 PM
Albright CharlesEVP/Chief Scientific OfficerNov 09Sale31.212287,11624,907Nov 10 04:13 PM
Albright CharlesEVP/Chief Scientific OfficerOct 15Sale31.393,00094,17025,135Oct 16 04:38 PM